nach oben

20.11.2023 | Original articles

Urantide alleviates atherosclerosis-related liver and kidney injury via the Wnt/β-catenin signaling pathway in ApoE(−/−) mice

verfasst von: Yu-hang Xu, Jia-yi Xie, Shen Huang, Tu Wang, Hai-peng Cui, Dr. Juan Zhao

Erschienen in: Herz

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the role of urantide in the prevention and treatment of atherosclerosis (AS)-related liver and kidney injury by antagonizing the urotensin II/urotensin receptor (UII/UT) system and regulating the Wnt/β-catenin signaling pathway.

Methods

Atherosclerotic ApoE^−/− mice were treated with 20 mg/kg, 30 mg/kg, and 40 mg/kg urantide for 14 days.

Results

When ApoE^−/− mice developed AS, significant pathological changes occurred in the liver and kidney, and the UII/UT system in tissue was highly activated; furthermore, the Wnt/β-catenin signalling pathway was activated, and proteins related to this signalling pathway, such as GSK-3β, AXIN2, CK‑1, and APC, were significantly downregulated. After urantide treatment, the pathological damage to the liver and kidney was effectively improved, the activity of the UII/UT system was effectively inhibited, and the expression of the Wnt/β-catenin signalling pathway and related proteins was restored. Wnt/β-catenin signals were mainly localized in the cytoplasm, renal tubules, and interstitium.

Conclusion

Urantide could improve AS-related liver and kidney injury by antagonizing the UII/UT system, and the improvements in liver and kidney function in atherosclerotic ApoE^−/− mice may be related to inhibition of the Wnt/β-catenin signalling pathway.

Nur mit Berechtigung zugänglich

Viola J, Soehnlein O (2015) Atherosclerosis—a matter of unresolved inflammation [J]. Semin Immunol 27(3):184–193CrossRefPubMed

Menghini R, Casagrande V, Cardellini M et al (2015) FoxO1 regulates asymmetric dimethylarginine via downregulation of dimethylaminohydrolase 1 in human endothelial cells and subjects with atherosclerosis [J]. Atherosclerosis 242(1):230–235CrossRefPubMed

Nelson CP, Hamby SE, Saleheen D et al (2015) Genetically determined height and coronary artery disease [J]. N Engl J Med 372(17):1608–1618CrossRefPubMedPubMedCentral

Gaudio E, Nobili V, Franchitto A et al (2012) Nonalcoholic fatty liver disease and atherosclerosis [J]. Intern Emerg Med 7(Suppl 3):S297–S305CrossRefPubMed

Farooqui Z, Ahmed F, Rizwan S et al (2017) Protective effect of nigella sativa oil on cisplatin induced nephrotoxicity and oxidative damage in rat kidney [J]. Biomed Pharmacother 85:7–15CrossRefPubMed

Huang P, Yan R, Zhang X et al (2019) Activating Wnt/β-catenin signaling pathway for disease therapy: challenges and opportunities [J]. Pharmacol Ther 196:79–90CrossRefPubMed

Clevers H, Nusse R (2012) Wnt/β-catenin signaling and disease [J]. Cell 149(6):1192–1205CrossRefPubMed

Zhang Y, Wang X (2020) Targeting the Wnt/β-catenin signaling pathway in cancer [J]. J Hematol Oncol 13(1):165CrossRefPubMedPubMedCentral

Wang Y, Fan X, Xing L et al (2019) Wnt signaling: a promising target for osteoarthritis therapy [J]. Cell Commun Signal 17(1):97CrossRefPubMedPubMedCentral

10.

Park HB, Kim JW, Baek KH (2020) Regulation of Wnt Signaling through ubiquitination and deubiquitination in Cancers [J]. Int J Mol Sci (21(11))

11.

Zhang L, Cheng H, Yue Y, Li S, Zhang D, He R (2018) H19 knockdown suppresses proliferation and induces apoptosis by regulating miR-148b/WNT/β-catenin in ox-LDL-stimulated vascular smooth muscle cells [J]. J Biomed Sci 25(1):11CrossRefPubMedPubMedCentral

12.

Vallée A, Vallée J, Lecarpentier Y (2019) Metabolic reprogramming in atherosclerosis: opposed interplay between the canonical WNT/β-catenin pathway and PPARγ [J]. J Mol Cell Cardiol 133:36–46CrossRefPubMed

13.

Wang F, Liu Z, Park SH et al (2018) Myeloid β‑catenin deficiency exacerbates atherosclerosis in low-density lipoprotein receptor-deficient mice [J]. Arterioscler Thromb Vasc Biol 38(7):1468–1478CrossRefPubMedPubMedCentral

14.

Ames RS, Sarau HM, Chambers JK et al (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J]. Nature 401(6750):282–286CrossRefPubMed

15.

Sun SL, Liu LM (2019) Urotensin II: an inflammatory cytokine [J]. J Endocrinol

16.

Schuster R, Steffen P, Dreyer B et al (2021) Identifying circulating Urotensin II and Urotensin II-related peptide-generating enzymes in the human plasma fraction Cohn IV‑4 [J]. J Proteome Res 20(12):5368–5378CrossRefPubMed

17.

Yu QQ, Cheng DX, Xu LR et al (2020) Urotensin II and urantide exert opposite effects on the cellular components of atherosclerotic plaque in hypercholesterolemic rabbits [J]. Acta Pharmacol Sin 41(4):546–553CrossRefPubMed

18.

Pereira-Castro J, Bras-Silva C, Fontes-Sousa AP (2019) Novel insights into the role of urotensin II in cardiovascular disease [J]. Drug Discov Today 24(11):2170–2180CrossRefPubMed

19.

Zhao J, Miao G, Wang T et al (2020) Urantide attenuates myocardial damage in atherosclerotic rats by regulating the MAPK signalling pathway [J]. Life Sci 262:118551CrossRefPubMed

20.

Wang T, Xie YQ, Miao GX et al (2020) Urotensin receptor antagonist urantide improves atherosclerosis-related kidney injury by inhibiting JAK2/STAT3 signaling pathway in rats [J]. Life Sci 247:117421CrossRefPubMed

21.

Li Y, Guo Z, Cui H et al (2021) Urantide prevents Ccl4-induced acute liver injury in rats by regulating the MAPK signalling pathway [J]. Mol Med Rep (24(4))

22.

Costa J, Alarcão J, Amaral-Silva A et al (2021) Atherosclerosis: the cost of illness in Portugal [J]. Rev Port Cardiol (engl Ed) 40(6):409–419CrossRefPubMed

23.

Cotter TG, Rinella M (2020) Nonalcoholic fatty liver disease 2020: the state of the disease [J]. Gastroenterology 158(7):1851–1864CrossRefPubMed

24.

Rewa O, Bagshaw SM (2014) Acute kidney injury-epidemiology, outcomes and economics [J]. Nat Rev Nephrol 10(4):193–207CrossRefPubMed

25.

Yu X, Xu M, Meng X et al (2020) Nuclear receptor PXR targets AKR1B7 to protect mitochondrial metabolism and renal function in AKI [J]. Sci Transl Med (12(543))

26.

Roth GA, Johnson C, Abajobir A et al (2017) Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015 [J]. J Am Coll Cardiol 70(1):1–25CrossRefPubMedPubMedCentral

27.

Sha X, Dai Y, Song X et al (2021) The opportunities and challenges of silica nanomaterial for atherosclerosis [J]. Int J Nanomedicine 16:701–714CrossRefPubMedPubMedCentral

28.

29.

Jegatheswaran J, Hadziomerovic A, Ruzicka M (2021) Acute severe renal artery stenosis presenting as acute kidney injury with severe hypertension and active urine sediment [J]. Can J Cardiol 37(10):1671–1673CrossRefPubMed

30.

Nasiri-Ansari N, Nikolopoulou C, Papoutsi K et al (2021) Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((−/−)) mice by activating autophagy and reducing ER stress and apoptosis [J]. Int J Mol Sci (22(2))

31.

Bi X, Du C, Wang X et al (2021) Mitochondrial damage-induced innate immune activation in vascular smooth muscle cells promotes chronic kidney disease-associated plaque vulnerability [J]. Adv Sci (weinh) 8(5):2002738CrossRefPubMed

32.

Schunk SJ, Floege J, Fliser D et al (2021) WNT-β-catenin signalling—a versatile player in kidney injury and repair [J]. Nat Rev Nephrol 17(3):172–184CrossRefPubMed

33.

Wojtaszek E, Oldakowska-Jedynak U, Kwiatkowska M et al (2021) Uremic toxins, oxidative stress, atherosclerosis in chronic kidney disease, and kidney transplantation [J]. Oxid Med Cell Longev 2021:6651367CrossRefPubMedPubMedCentral

34.

Russell JO, Monga SP (2018) Wnt/beta-Catenin signaling in liver development, homeostasis, and pathobiology [J]. Annu Rev Pathol 13:351–378CrossRefPubMed

35.

Collins R, Reith C, Emberson J et al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy [J]. Lancet 388(10059):2532–2561CrossRefPubMed

Titel: Urantide alleviates atherosclerosis-related liver and kidney injury via the Wnt/β-catenin signaling pathway in ApoE(−/−) mice
verfasst von: Yu-hang Xu
Jia-yi Xie
Shen Huang
Tu Wang
Hai-peng Cui
Dr. Juan Zhao
Publikationsdatum: 20.11.2023
Verlag: Springer Medizin
Erschienen in: Herz
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-023-05219-w

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen